Acquisition momentum LIDDS strategically expanded its oncology focus by acquiring Noviga Research AB in January 2024, signaling a push into cancer therapeutics and potential cross-sell opportunities for NanoZolid-based local delivery in oncology trials.

NanoZolid potential The core technology enables local, controlled drug release for up to six months, presenting a compelling competitive angle for pharma and biotech partners seeking improved local delivery for oncology and other indications.

Leadership shifts Frequent CEO and leadership changes suggest evolving strategy and potential pivots; engaging with multiple executives or interim leaders may require a broad outreach approach to align with current priorities and partnership interests.

Early-stage funding With modest revenue and around four million dollars in funding, LIDDS is in a growth phase receptive to partnerships, co-development, or licensing deals to accelerate R&D programs and expand clinical pipelines.

Strategic partnerships Past collaborations with Johnson & Johnson Enterprise Innovation indicate openness to external collaboration; target biotech and pharma companies seeking innovative drug delivery platforms or oncology trial enhancements.